Walmart Slides Most Since 2022 on Slowing US Sales Growth

Bloomberg's Poonam Goyal said Walmart's earnings miss is largely due to lagging pharmaceutical sales impacted by new federal negotiations aimed at delivering lower drug prices. Goyal said that it's an issue that both the company and investors are expecting to continue affecting sales. Goyal said that Walmart could have the opportunity to calm concerns about flagging US sales growth by focusing on bringing in customers with competitive pricing. (Source: Bloomberg)

Read it at Bloomberg Markets ↗

← Front page